Variant form of urate oxidase and use thereof
AssigneeSavient Pharmaceuticals, Inc.
InventorsJacob Hartman, Simona Mendelovitz
Life of this patent
Estimating the term…
Abstract
The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.
Claims28
A method for lowering elevated uric acid levels in a patient comprising administering to said patient an intravenous injection of PEG-uricase having a dosage from about 0.5 to about 24 mg of uricase, the uricase comprising the amino acid sequence of SEQ ID NO:
- 7, wherein said administration takes place from about every 2 to 4 weeks.
A method for lowering elevated uric acid levels in a patient comprising administering to said patient an intravenous injection of PEG-uricase having a dosage from about 4 to about 12 mg of uricase, the uricase consisting of the amino acid sequence of SEQ ID NO:
- 7, wherein the PEG-uricase administration takes place from about every 2 to 4 weeks.
Dependencies are inferred from the claim text.